Skip to main content Accessibility help
×
×
Home

Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative?

  • Jerome R. Hoffman (a1)
Extract

Adapting information from research to clinical practice can be difficult, and we are often forced to decide whether benefits reported in selected trials are adequate to justify widespread application of the intervention studied. This is particularly problematic when the “evidence” is scanty, the degree of benefit apparently small (if real), and the treatment potentially dangerous. In addition, it is always important to consider whether community physicians can replicate the success described in research studies, which are typically performed by experts working in the controlled setting of a well-funded study.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative?
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative?
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative?
      Available formats
      ×
Copyright
Corresponding author
UCLA Emergency Medicine Center, 924 Westwood Blvd., Ste. 300, Los Angeles CA 90077; jrh@ucla.edu
References
Hide All
1.Canadian Association of Emergency Physicians Committee on Thrombolytic Therapy for Acute Ischemic Stroke. Thrombolytic therapy for acute ischemic stroke. CJEM 2001;3(1):812.
2.American Heart Association. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2000;102(Suppl I). Available: http://circ.ahajournals.org/content/vol102/suppl_1/#ECC_GUIDELINES (accessed 2001 June 02).
3.Tissue Plasminogen Activator for Acute Ischemic Stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):15817.
4.Kay, R, Wong, KS, Yu, YL, Chan, YW, Tsoi, TH, Ahuja, AT, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333(24):158893
5.Marler, JR, Tilley, BC, Lu, M, Brott, TG, Lyden, PC, Grotta, JC, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000;55:164955.
6.Jorgensen, HS, Nakayama, H, Kammersgaard, LP, Raaschou, HO, Olsen, TS.Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model. BMJ 1999;319:2889.
7.Hoffman, JR.Predicted impact of intravenous thrombolysis. Another trial is needed [letter]. BMJ 2000;320:1007.
8.Libman, RB, Wirkowski, E, Alvir, J, Rao, TH.Conditions that mimic stroke in the emergency department: implications for acute stroke trials. Arch Neurol 1995;52(11):111922.
9.Schriger, DL, Kalafut, M, Starkman, S, Krueger, M, Saver, JL.Cranial computed tomography interpretation in acute stroke: physician accuracy in determining eligibility for thrombolytic therapy. JAMA 1998;279:12937.
10.Katzan, IL, Furlan, AJ, Lloyd, LE, Frank, JI, Harper, DL, Hinchey, JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283(19):11518.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Canadian Journal of Emergency Medicine
  • ISSN: -
  • EISSN: 1481-8035
  • URL: /core/journals/canadian-journal-of-emergency-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed